Department of Neuroscience, Canadian Centre for Behavioural Neuroscience, University of Lethbridge, Lethbridge, AB, Canada.
Department of Basic Sciences in Rehabilitation, School of Rehabilitation Sciences, Iran University of Medical Science (IUMS), Tehran, Iran.
Mov Disord. 2020 Apr;35(4):537-550. doi: 10.1002/mds.28000. Epub 2020 Feb 13.
PD is a progressive and complex neurological disorder with heterogeneous symptomatology. PD is characterized by classical motor features of parkinsonism and nonmotor symptoms and involves extensive regions of the nervous system, various neurotransmitters, and protein aggregates. Extensive evidence supports auditory dysfunction as an additional nonmotor feature of PD. Studies indicate a broad range of auditory impairments in PD, from the peripheral hearing system to the auditory brainstem and cortical areas. For instance, research demonstrates a higher occurrence of hearing loss in early-onset PD and evidence of abnormal auditory evoked potentials, event-related potentials, and habituation to novel stimuli. Electrophysiological data, such as auditory P3a, also is suggested as a sensitive measure of illness duration and severity. Improvement in auditory responses following dopaminergic therapies also indicates the presence of similar neurotransmitters (i.e., glutamate and dopamine) in the auditory system and basal ganglia. Nonetheless, hearing impairments in PD have received little attention in clinical practice so far. This review summarizes evidence of peripheral and central auditory impairments in PD and provides conclusions and directions for future empirical and clinical research. © 2020 International Parkinson and Movement Disorder Society.
PD 是一种进行性且复杂的神经退行性疾病,具有异质性的症状。PD 的特征是经典的帕金森运动特征和非运动症状,涉及广泛的神经系统区域、各种神经递质和蛋白质聚集体。大量证据支持听觉功能障碍是 PD 的另一个非运动特征。研究表明,PD 存在广泛的听觉障碍,从外周听觉系统到听觉脑干和皮质区域。例如,研究表明,早发性 PD 听力损失的发生率更高,并且存在异常的听觉诱发电位、事件相关电位和对新刺激的习惯化。听觉 P3a 等电生理数据也被认为是疾病持续时间和严重程度的敏感衡量指标。多巴胺能治疗后听觉反应的改善也表明听觉系统和基底神经节中存在类似的神经递质(即谷氨酸和多巴胺)。尽管如此,迄今为止,PD 的听力障碍在临床实践中还没有受到太多关注。本综述总结了 PD 中周围和中枢听觉障碍的证据,并为未来的实证和临床研究提供了结论和方向。© 2020 国际帕金森病和运动障碍协会。